Trials / Completed
CompletedNCT02053896
A Switch-Over Study of the Safety and Efficacy of ISU302 in Patients With Type 1 Gaucher Disease
A Phase 2 Multi-Center, Open-Label, Switch-Over Trial to Evaluate the Safety and Efficacy of ISU302 in Patients With Type 1 Gaucher Disease Previously Treated With Imiglucerase
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 5 (actual)
- Sponsor
- ISU Abxis Co., Ltd. · Industry
- Sex
- All
- Age
- 8 Years – 29 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of ISU302 in patients with Type 1 Gaucher disease previously treated with Imiglucerase.
Conditions
Timeline
- Start date
- 2011-05-01
- Primary completion
- 2012-02-01
- Completion
- 2012-02-01
- First posted
- 2014-02-04
- Last updated
- 2014-02-04
Source: ClinicalTrials.gov record NCT02053896. Inclusion in this directory is not an endorsement.